In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Arrowhead buys another RNAi business, this time from Novartis, for $35mm

Executive Summary

For the second time, Arrowhead Research Corp. is taking on unwanted RNAi assets from Big Pharma; in this case, Novartis AG divested its RNAi R&D pipeline and related assets. Novartis, which will assign Arrowhead patents and patent applications, announced in April 2014 that it was significantly cutting internal drug discovery activities in the RNAi field.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Earnout
    • Payment Includes Cash
    • Payment Includes Stock

Related Companies